A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

被引:1908
作者
Sharma, Sreenath V. [1 ]
Lee, Diana Y. [1 ]
Li, Bihua [1 ]
Quinlan, Margaret P. [1 ]
Takahashi, Fumiyuki [1 ]
Maheswaran, Shyamala [1 ]
McDermott, Ultan [1 ]
Azizian, Nancy [1 ]
Zou, Lee [1 ]
Fischbach, Michael A. [1 ]
Wong, Kwok-Kin [2 ]
Brandstetter, Kathleyn [2 ]
Wittner, Ben [1 ]
Ramaswamy, Sridhar [1 ]
Classon, Marie [1 ]
Settleman, Jeff [1 ]
机构
[1] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
STEM-CELLS; THERAPEUTIC RESISTANCE; HISTONE MODIFICATION; GROWTH; INSULIN; MECHANISMS; SENSITIVITY; RETREATMENT; INHIBITORS; DISEASE;
D O I
10.1016/j.cell.2010.02.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Accumulating evidence implicates heterogeneity within cancer cell populations in the response to stressful exposures, including drug treatments. While modeling the acute response to various anticancer agents in drug-sensitive human tumor cell lines, we consistently detected a small subpopulation of reversibly "drug-tolerant" cells. These cells demonstrate >100-fold reduced drug sensitivity and maintain viability via engagement of IGF-1 receptor signaling and an altered chromatin state that requires the histone demethylase RBP2/KDM5A/Jarid1A. This drug-tolerant phenotype is transiently acquired and relinquished at low frequency by individual cells within the population, implicating the dynamic regulation of phenotypic heterogeneity in drug tolerance. The drug-tolerant subpopulation can be selectively ablated by treatment with IGF-1 receptor inhibitors or chromatin-modifying agents, potentially yielding a therapeutic opportunity. Together, these findings suggest that cancer cell populations employ a dynamic survival strategy in which individual cells transiently assume a reversibly drug-tolerant state to protect the population from eradication by potentially lethal exposures.
引用
收藏
页码:69 / 80
页数:12
相关论文
共 42 条
  • [41] Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity
    Vermeulen, L.
    Todaro, M.
    Mello, F. de Sousa
    Sprick, M. R.
    Kemper, K.
    Alea, M. Perez
    Richel, D. J.
    Stassi, G.
    Medema, J. P.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (36) : 13427 - 13432
  • [42] Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: A report of three cases
    Yano, S
    Nakataki, E
    Ohtsuka, S
    Inayama, M
    Tomimoto, H
    Edakuni, N
    Kakiuchi, S
    Nishikubo, N
    Muguruma, H
    Sone, S
    [J]. ONCOLOGY RESEARCH, 2005, 15 (02) : 107 - 111